CLEM Clinical and Experimental Medicine’s Post

INSIDE LOOK 👀 Read more of the latest research from the upcoming issue (September 9): Is the achievement of sputum culture conversion in patients with Mycobacterium avium complex pulmonary disease (MAC-PD) and cavitary lesions associated with the prognosis? Read the full original research in the September issue to learn more: https://hubs.ly/Q02NR5wG0 #MedEd #JournalCHEST

In this interview, Prof. Dr. Georg Schett, Uniklinikum Erlangen and FAU Erlangen-Nürnberg, discusses why CAR T is a good fit for autoimmune diseases, and what hurdles they’re facing for the future. "Patients don’t have to think about their disease every day. They don’t have to take drugs anymore. They don’t feel their immune system suppressed." Read the full interview here: https://lnkd.in/emP7kTEC #IO360Summit #immunooncology #clinicalresearch #clinicaltrials #CART

September is Pulmonary Fibrosis Awareness Month. More than 250K Americans are living with PF, and over 50K diagnoses occur annually. There is no known cure for PF, and although some effective treatments are available, further research is needed. The Pulmonary Fibrosis Foundation sponsored PFF Registry provides a crucial #clinicalresearch tool to discover the causes of Interstitial Lung Disease and improve treatments. https://lnkd.in/gfrVfAh4 #PFMonth #BlueUp4PF #PulmonaryFibrosisAwarenessMonth

Learn how our experience and differentiated science is enabling us to design and develop a #CART 2.0 product for autoimmune disease that is scalable and could eliminate or reduce lymphodepletion to meet the unique needs of patients. #celltherapy #immunotherapy   Uncover the Potential of ALLO-329: Allogene.com/Pipeline

Natural history studies can support approvals of new rare disease therapies. If you integrate these real-world, protocol-driven studies into the early clinical development planning process, there will be a host of benefits: https://bit.ly/3VYvmJr #raredisease #realworldstudies

Interventions for valvular disease: Highlights of #EuroPCR 2024 Chris Cook hosts Nicolas Dumonteil and Bernard Prendergast as they discuss amongst others: 🟣 record-breaking abstracts and cases, demonstrating expertise in #TAVI, #mitral, and #tricuspid procedures 🟣 LIVE cases, especially in complex TAVI scenarios, reflecting everyday practice 🟣 the crucial role of #imaging in patient selection and procedure guidance 🟣 key studies like NOTION-II and LANDMARK, and the groundbreaking ShortCut trial addressing degenerated aortic bioprostheses, and much more! https://lnkd.in/duCEPVxm

The GKPTN + CAPTIVATE trial will efficiently test combination therapies for people with kidney disease. This trial protocol describes the design and baseline results of the GKPTN and the design of the global adaptive platform trial CAPTIVATE. https://ja.ma/3ON9cXc

The phase III KEYNOTE-A18 trial reports extended survival with the addition of pembrolizumab to concurrent #chemoradiotherapy (CRT) in locally advanced #CervicalCancer, and supports this strategy as a new standard of care in patients with high-risk disease. Data from a second interim analysis presented at #ESMO24 showed that while median OS was not reached in either arm, the 36-month OS rate was significantly improved with pembrolizumab plus CRT versus CRT alone. The treatment offers a greater chance of cure compared with existing therapies, comments Remi Nout. 📌 Read the full news on the #ESMODailyReporter https://ow.ly/PIFE50TnAuR

Natural history studies can support approvals of new rare disease therapies. If you integrate these real-world, protocol-driven studies into the early clinical development planning process, there will be a host of benefits: https://bit.ly/4cwtkas #raredisease #clinicalstudies

Tackling Calcium in Peripheral Vascular Disease with IVL Webinar with Shockwave TONIGHT AT 7PM Join our expert panel to explore current issues and challenges in calcification and see how IVL can play a crucial role in improving outcomes for patients. Learn from case studies, discover tips and tricks to optimize outcomes and join the discussion. Duration: 2 hours Price: Free 🔗 Book via the link in the comments